



ProFound AI™ Risk

Revolutionizing Personalized Screening

ProFound AI™ Risk is the first and only clinical decision support tool that provides an accurate two-year, breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram.

The easy-to-implement solution provides superior insights¹ that empower clinicians to tailor a woman’s breast screening regimen and potentially identify cancers earlier.

ProFound AI Risk uniquely combines a range of risk factors, offering superior performance in assessing short-term risk compared to traditional breast cancer risk models.²

Superior Accuracy



An AUC³ of 0.73¹ offers superior accuracy² compared to traditional risk assessment models.

Simplified Workflow



Efficient and easy to implement solution provides a rapid short-term risk estimate based on the mammographic exam.

Personalized Care



Improved model delivers operational efficiency and enhances patient care.

*CE Mark approved

ProFound AI™ Risk

Revolutionizing Personalized Screening

Personalized Screening Made Easy with ProFound AI Risk

ProFound AI Risk can be seamlessly implemented in any facility with a screening mammography program. All that is needed is a standard bilateral two-view full-field digital mammogram.

ProFound AI Risk incorporates multiple risk factors found in a screening mammogram:

Age



Breast Density



Subtle Mammographic Features



ProFound AI Risk provides physicians with a broad view of each patient's individual risk of breast cancer.

Proven Solution Uniquely Positioned for Personalized Screening

ProFound AI Risk offers proven results that rapidly provide physicians and patients with an accurate two-year absolute breast cancer risk score and risk category (low, general, moderate and high).¹

The field of mammography is moving from age-based screening to more individualized risk-based screening. ProFound AI Risk is a leading-edge solution that enables clinicians to easily adapt to evolving screening practices and personalized patient care.

One Comprehensive Breast Cancer Detection and Treatment Partner

iCAD's product portfolio offers innovative solutions to support breast cancer detection, measure breast density, assess personalized risk, and provide targeted radiation therapy. Our technologies offer clinically proven benefits to clinicians and patients, and are designed to optimize efficiency, enhance the patient experience, and improve outcomes.

References:

1. iCAD data on file.
2. Brentall A, Harkness E, Astley S et al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. *Breast Cancer Res.* 2015; 17,147.
3. Area under the receiver operating characteristic curve.